We are live on ! Find out more
RPSM

Royalty Pharma Sub-Manager Portfolio holdings

AUM $242M
This Fund
S&P 500
This Quarter Est. Return
-10.01%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$173M
AUM Growth
+$1.45M
Cap. Flow
+$25.3M
Cap. Flow %
14.62%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ZBIO
Zenas BioPharma
ZBIO
+$25.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
Cytokinetics
CYTK
$10.8B
$64.6M 37.4%
980,392
– –
ZBIO
2
Zenas BioPharma
ZBIO
$2.2B
$46.7M 27.02%
2,388,150
+1,125,000
+89% +$25.3M
BCRX icon
3
BioCryst Pharmaceuticals
BCRX
$2.51B
$36.6M 21.19%
3,846,154
– –
BHVN icon
4
Biohaven
BHVN
$2.17B
$24.8M 14.38%
2,936,507
– –

Similar funds

FH
Financial Harvest Winter Park, Florida $242M AUM 23.25% 1-Year Est. Return
SA
Sunesis Advisors Overland Park, Kansas $242M AUM 15.73% 1-Year Est. Return
TFP
TrueWealth Financial Partners Bellevue, Washington $242M AUM 14.39% 1-Year Est. Return
WCP
Wealthcare Capital Partners West Chester, Pennsylvania $242M AUM 18.96% 1-Year Est. Return
UI
Unconventional Investor Portsmouth, New Hampshire $242M AUM 18.7% 1-Year Est. Return
ACP
Arcus Capital Partners Atlanta, Georgia $242M AUM 20.33% 1-Year Est. Return
DEA
DoubleLine ETF Adviser Tampa, Florida $242M AUM 7.85% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $242M AUM 17.72% 1-Year Est. Return

Royalty Pharma Sub-Manager's Q1 2026 Portfolio in Review

As of Q1 2026, Royalty Pharma Sub-Manager held 4 positions worth $173M, up 0.85% from $171M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Royalty Pharma Sub-Manager deployed $25.3M of net new capital in Q1 2026, adding to 1 existing holding.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Royalty Pharma Sub-Manager added most to Zenas BioPharma in Q1 2026, an estimated $25.3M increase.
  • Royalty Pharma Sub-Manager's ten largest holdings make up 100% of its $173M portfolio in Q1 2026.
  • Royalty Pharma Sub-Manager opened 0 new positions and closed 0 in Q1 2026.
  • Royalty Pharma Sub-Manager's portfolio value rose 0.85% quarter-over-quarter to $173M.

Based on Royalty Pharma Sub-Manager's 13F filing for Q1 2026, filed 14 May 2026.